Last reviewed · How we verify
Abatacept plus
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation.
Abatacept is a fusion protein that blocks T-cell costimulation by binding to CD80/CD86 on antigen-presenting cells, thereby inhibiting T-cell activation and proliferation. Used for Rheumatoid arthritis, Polyarticular juvenile idiopathic arthritis, Psoriatic arthritis.
At a glance
| Generic name | Abatacept plus |
|---|---|
| Also known as | Orencia |
| Sponsor | Massachusetts General Hospital |
| Drug class | T-cell costimulation modulator |
| Target | CD80/CD86 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Abatacept (CTLA4-Ig) acts as a selective costimulation modulator that interrupts the second signal required for full T-cell activation. By binding to CD80 and CD86 molecules on dendritic cells and other antigen-presenting cells, it prevents interaction with CD28 on T cells, reducing inflammatory cytokine production and T-cell proliferation. This mechanism makes it effective in autoimmune and inflammatory conditions where T-cell dysregulation is central to pathogenesis.
Approved indications
- Rheumatoid arthritis
- Polyarticular juvenile idiopathic arthritis
- Psoriatic arthritis
- Ankylosing spondylitis
- Systemic lupus erythematosus (Phase 3)
Common side effects
- Infection (upper respiratory, urinary tract)
- Headache
- Nausea
- Dizziness
- Hypertension
Key clinical trials
- Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases (PHASE1, PHASE2)
- Assessment of Biomarker-Guided CNI Substitution In Kidney Transplantation (PHASE2)
- Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (PHASE3)
- Treatment Tapering in JIA With Inactive Disease (PHASE3)
- Study of COYA 302 for the Treatment of ALS (PHASE2)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Treatment of Antibody-Mediated Rejection (ABMR) With CarBel (PHASE2)
- Advancing Transplantation Outcomes in Children (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |